1.The first clinical trial that assesses stem cells in a transplantation setting
ID: 164573 • Letter: 1
Question
1.The first clinical trial that assesses stem cells in a transplantation setting is using HSCs for the treatment of heart attack. Why are HSCs used and not cardiac stem cells?
2.Neurogenin is a bHLH transcription factor. What does bHLH stand for?
3.You have isolated MSCs from mice and cultured them in vitro for 5 passages. In passage 6 you notice that p53 levels are high and that your cells form a lot of actin stress fibers. Do your MSCs show in vitro or in vivo aging? Explain the difference.
Please explain. Thank you in advance.
Explanation / Answer
1. HSCs can be obtained easily and in high amounts from bone marrow. It is difficult to obtain cardiac stem cells until it is for a specific purpose. They would be wasted if used for trials.
2. bHLH stands for basic helix-loop-helix, which is a structural motif. It shows how the protein folds into characteristic shape.
3. in vitro aging of MSC often shows characters which can be visualized such as telomere shortening. However, changes at the physiological level often fall into in vivo aging, which includes increase in p53 levels.
Related Questions
Navigate
Integrity-first tutoring: explanations and feedback only — we do not complete graded work. Learn more.